Pfizer and Array BioPharma have announced Pfizer will acquire Array, a commercial stage biopharma with operations in Colorado, Massachusetts and North Carolina focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. Pfizer has agreed to acquire Array for $48 per share in […]

Cambridge-based Comet Therapeutics has raised $28.5 million in Series A funding to develop a broad portfolio of drug candidates built around the unique ability to re-engineer Coenzyme A (CoA)-related metabolism. Comet’s platform has numerous potential applications including metabolic disorders, neuro-metabolic diseases, immuno-metabolic conditions and other life-threatening diseases. CoEnzyme A (CoA) is essential in numerous cellular […]

Merck has announced that it plans to acquire Lexington-based Tilos Therapeutics, a biopharma developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases. TGFβ is a potent cytokine believed to play an important role in the development of cancer and fibrotic diseases. TGFβ is secreted as a complex with […]

Vertex and CRISPR Therapeutics have expanded their collaboration and entered into an exclusive licensing agreement to discover and develop gene editing therapies for the treatment of Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1). In addition, Vertex will acquire privately-held Exonics, a company focused on creating transformative gene editing therapies to repair mutations […]

bluebird bio has announced that the European Commission (EC) has granted conditional marketing authorization for Zynteglo™,  a gene therapy for certain patients with transfusion-dependent β-thalassemia (TDT). The authorization is valid in all 28 member states of the EU as well as Iceland, Liechtenstein and Norway. TDT is a severe genetic disease caused by mutations in the […]

Chicago-based, investment management firm Harrison Street has entered a ground lease with MIT for the three-building, 677K SF Osborn Triangle life science complex near Kendall Square. The deal surpassed $1B, or just over $1,600/SF, setting a neighborhood portfolio price record, according to sources familiar with the deal. “Osborn Triangle is a one-of-a-kind complex serving as […]

Vertex Pharmaceuticals and Kymera Therapeutics have announced that the two companies have entered into a four-year strategic research and development collaboration to advance small molecule protein degraders against multiple targets.  The collaboration will leverage Kymera’s expertise in targeted protein degradation and its proprietary PegasusTM drug discovery platform and Vertex’s scientific, clinical, and regulatory capabilities to […]

Gilead Sciences and Goldfinch Bio have announced a strategic collaboration to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases. Under the multi-year collaboration, Gilead has exclusive options to license worldwide rights to certain products directed toward targets emerging from Goldfinch’s proprietary Kidney Genome Atlas™ (KGA), […]

ElevateBio has established ElevateBio BaseCamp, a single R&D, process development and cGMP manufacturing company, to address the process development and manufacturing barriers that can impede the successful development of cell and gene therapies. BaseCamp is providing these and other services across ElevateBio’s portfolio companies and selected strategic partners, enabling them to access state of the […]

Servier Pharmaceuticals, a U.S. subsidiary of the global French pharmaceutical company Servier Group, has officially opened its American headquarters in Boston’s new Innovation District. The facility already employs 100 professionals in marketing, business development, R&D and strategic support functions. That figure is projected to double within five years. Servier Group also established the first office […]